KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder.

Kelly Covert, Shelby Brooks, Jessica E Burchette

Ann Pharmacother 60(4) 378-393

PMID41190453
PMCID-
DOI10.1177/10600280251382202
发表日期2025-11-05
摘要

摘要

OBJECTIVE: To summarize the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates and data for novel therapies/interventions. DATA SOURCES: Articles gathered from MEDLINE, Cochrane Reviews, and PubMed databases. Package inserts for novel agents were utilized. Search terms included chronic obstructive pulmonary disorder (COPD), inhaled corticosteroids (ICS), inhaled long-acting muscarinic antagonists (LAMA), inhaled long-acting beta-2 agonists (LABA), dupilumab, ensifentrine, icenticaftor, and itepekimab. STUDY SELECTION AND DATA EXTRACTION: English-language primary literature and review articles evaluated. GOLD guidelines from 2001 to 2025 were utilized. DATA SYNTHESIS: Six meta-analyses and one randomized controlled trial (RCT) favor initial LAMA/LABA combination over monocomponent agents. Three RCTs note increased ICS efficacy with blood eosinophils >300 cells/µL. One meta-analysis and 8 RCTs address vaccinations, specifically RSV and pneumococcal. Novel medications ensifentrine, dupilumab, and icenticaftor each have 2 RCTs in patients with persistent symptoms despite optimized LAMA/LABA and ICS. Itepekimab is in phase 3 studies. The CAPTURE tool has 2 RCTs validating screening patients with unrecognized COPD. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Identification of notable changes to optimal COPD management, including LABA/LAMA therapy, judicious ICS use, updated vaccine recommendations, and potential roles for ensifentrine and dupilumab. CONCLUSION AND RELEVANCE: Evidence supports LABA/LAMA with nuanced use of ICS. Several novel therapies are approved or are being studied for patients suboptimally controlled. Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。